FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911325844> ?p ?o ?g. }

• W2911325844 endingPage "S401" @default.
• W2911325844 startingPage "S400" @default.
• W2911325844 abstract "This study aimed to compare the real-world clinical effectiveness and safety of vedolizumab (VDZ), a gut-selective anti-α4β7-integrin, and anti-tumour necrosis factor (TNF) agents in biologic (bio)-naïve ulcerative colitis (UC) patients. A retrospective chart review study was conducted in adult (≥18 years), bio-naïve UC pts treated with VDZ or anti-TNF (June 2014 to February 2018) in Canada, Greece and the USA. Data were collected from treatment (Tx) initiation to earliest of death, chart abstraction date or 6 months post-Tx discontinuation. Cumulative rates of clinical response, clinical remission, mucosal healing, Tx persistence and dose escalations were estimated over 24 months (Kaplan–Meier method). Incidence rates (per 100 person-years [PYs]) of UC exacerbations, colectomy, serious adverse events (SAEs) and serious infections (SIs) were assessed. A Cox proportional hazards model was used to compare outcomes with adjustments for baseline confounders: age, sex, albumin, C-reactive protein, disease location and duration, UC-related hospitalisations (prior 12 mo) and disease severity; adjusted hazard ratios (HR) with 95% confidence interval are reported. Overall, 527 UC patients (VDZ: 325; anti-TNF: 202 [adalimumab: 58, infliximab: 120, golimumab: 24]) from 37 sites were included (median [min–max] follow-up [mo]: VDZ, 16.1 (3.0–47.0); anti-TNF, 20.0 [3.5–50.6]). Baseline characteristics are shown in Table 1. Table 1. Baseline characteristics of real-world biologic-naive ulcerative colitis patients treated with vedolizumab and anti-TNF agents At 24 months, cumulative rates of clinical response (91% vs. 86%), clinical remission (79% vs. 66%) and mucosal healing (92% vs. 84%) were high in VDZ and anti-TNF patients, respectively, and did not differ significantly between groups. Higher Tx persistence (75% vs. 54%; p < 0.0001) and similar rates of dose escalations (25% vs. 31%; p < 0.05) occurred in VDZ vs. anti-TNF patients. The incidence rate (per 100 PYs) of UC exacerbations (28.3 vs. 43.9) and SAEs (4.9 vs. 10.4) were significantly (p < 0.05) lower in VDZ vs. anti-TNF patients but similar for colectomy (1.8 vs. 2.2) and SIs (1.9 vs. 2.2). Adjusted HR for outcomes are shown in Table 2. Table 2. Clinical effectiveness and safety of vedolizumab and anti-TNF agents in real-world biologic-naïve ulcerative colitis patients. VDZ and anti-TNF have similar rates of clinical effectiveness in bio-naïve UC patients in real-world clinical practice. Bio-naïve UC patients receiving VDZ are significantly more likely to persist with Tx and experience fewer exacerbations and SAEs than anti-TNF patients." @default.
• W2911325844 created "2019-02-21" @default.
• W2911325844 creator A5003048730 @default.
• W2911325844 creator A5007816069 @default.
• W2911325844 creator A5018431342 @default.
• W2911325844 creator A5024444580 @default.
• W2911325844 creator A5028285577 @default.
• W2911325844 creator A5034738993 @default.
• W2911325844 creator A5042677752 @default.
• W2911325844 creator A5043128110 @default.
• W2911325844 creator A5062818239 @default.
• W2911325844 creator A5063696008 @default.
• W2911325844 creator A5064719712 @default.
• W2911325844 creator A5075986612 @default.
• W2911325844 creator A5087438907 @default.
• W2911325844 creator A5089988734 @default.
• W2911325844 date "2019-01-25" @default.
• W2911325844 modified "2023-10-02" @default.
• W2911325844 title "P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study" @default.
• W2911325844 doi "https://doi.org/10.1093/ecco-jcc/jjy222.697" @default.
• W2911325844 hasPublicationYear "2019" @default.
• W2911325844 type Work @default.
• W2911325844 sameAs 2911325844 @default.
• W2911325844 citedByCount "6" @default.
• W2911325844 countsByYear W29113258442019 @default.
• W2911325844 countsByYear W29113258442021 @default.
• W2911325844 countsByYear W29113258442022 @default.
• W2911325844 crossrefType "journal-article" @default.
• W2911325844 hasAuthorship W2911325844A5003048730 @default.
• W2911325844 hasAuthorship W2911325844A5007816069 @default.
• W2911325844 hasAuthorship W2911325844A5018431342 @default.
• W2911325844 hasAuthorship W2911325844A5024444580 @default.
• W2911325844 hasAuthorship W2911325844A5028285577 @default.
• W2911325844 hasAuthorship W2911325844A5034738993 @default.
• W2911325844 hasAuthorship W2911325844A5042677752 @default.
• W2911325844 hasAuthorship W2911325844A5043128110 @default.
• W2911325844 hasAuthorship W2911325844A5062818239 @default.
• W2911325844 hasAuthorship W2911325844A5063696008 @default.
• W2911325844 hasAuthorship W2911325844A5064719712 @default.
• W2911325844 hasAuthorship W2911325844A5075986612 @default.
• W2911325844 hasAuthorship W2911325844A5087438907 @default.
• W2911325844 hasAuthorship W2911325844A5089988734 @default.
• W2911325844 hasBestOaLocation W29113258441 @default.
• W2911325844 hasConcept C126322002 @default.
• W2911325844 hasConcept C17991360 @default.
• W2911325844 hasConcept C197934379 @default.
• W2911325844 hasConcept C207103383 @default.
• W2911325844 hasConcept C2776207728 @default.
• W2911325844 hasConcept C2776667177 @default.
• W2911325844 hasConcept C2777138892 @default.
• W2911325844 hasConcept C2778260677 @default.
• W2911325844 hasConcept C2778715236 @default.
• W2911325844 hasConcept C2779134260 @default.
• W2911325844 hasConcept C2780132546 @default.
• W2911325844 hasConcept C2780479503 @default.
• W2911325844 hasConcept C2781290027 @default.
• W2911325844 hasConcept C44249647 @default.
• W2911325844 hasConcept C50382708 @default.
• W2911325844 hasConcept C71924100 @default.
• W2911325844 hasConcept C72563966 @default.
• W2911325844 hasConcept C88879693 @default.
• W2911325844 hasConcept C90924648 @default.
• W2911325844 hasConceptScore W2911325844C126322002 @default.
• W2911325844 hasConceptScore W2911325844C17991360 @default.
• W2911325844 hasConceptScore W2911325844C197934379 @default.
• W2911325844 hasConceptScore W2911325844C207103383 @default.
• W2911325844 hasConceptScore W2911325844C2776207728 @default.
• W2911325844 hasConceptScore W2911325844C2776667177 @default.
• W2911325844 hasConceptScore W2911325844C2777138892 @default.
• W2911325844 hasConceptScore W2911325844C2778260677 @default.
• W2911325844 hasConceptScore W2911325844C2778715236 @default.
• W2911325844 hasConceptScore W2911325844C2779134260 @default.
• W2911325844 hasConceptScore W2911325844C2780132546 @default.
• W2911325844 hasConceptScore W2911325844C2780479503 @default.
• W2911325844 hasConceptScore W2911325844C2781290027 @default.
• W2911325844 hasConceptScore W2911325844C44249647 @default.
• W2911325844 hasConceptScore W2911325844C50382708 @default.
• W2911325844 hasConceptScore W2911325844C71924100 @default.
• W2911325844 hasConceptScore W2911325844C72563966 @default.
• W2911325844 hasConceptScore W2911325844C88879693 @default.
• W2911325844 hasConceptScore W2911325844C90924648 @default.
• W2911325844 hasIssue "Supplement_1" @default.
• W2911325844 hasLocation W29113258441 @default.
• W2911325844 hasOpenAccess W2911325844 @default.
• W2911325844 hasPrimaryLocation W29113258441 @default.
• W2911325844 hasRelatedWork W2006826205 @default.
• W2911325844 hasRelatedWork W2042655884 @default.
• W2911325844 hasRelatedWork W2105263940 @default.
• W2911325844 hasRelatedWork W2138584845 @default.
• W2911325844 hasRelatedWork W2152399325 @default.
• W2911325844 hasRelatedWork W2326143279 @default.
• W2911325844 hasRelatedWork W2327255580 @default.
• W2911325844 hasRelatedWork W2565544404 @default.
• W2911325844 hasRelatedWork W3147462706 @default.
• W2911325844 hasRelatedWork W4213385218 @default.
• W2911325844 hasVolume "13" @default.
• W2911325844 isParatext "false" @default.
• W2911325844 isRetracted "false" @default.

• next